Breaking News Instant updates and real-time market news.

TEVA

Teva

$42.96

-1.32 (-2.98%)

, REGN

Regeneron

$371.68

-4.11 (-1.09%)

07:00
10/17/16
10/17
07:00
10/17/16
07:00

Teva, Regeneron say FDA places Phase 2b fasinumab study on clinical hold

TEVA

Teva

$42.96

-1.32 (-2.98%)

REGN

Regeneron

$371.68

-4.11 (-1.09%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

TEVA Teva
$42.96

-1.32 (-2.98%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
REGN Regeneron
$371.68

-4.11 (-1.09%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target

TODAY'S FREE FLY STORIES

SAJA

Sajan

$3.99

0.19 (5.00%)

07:55
04/26/17
04/26
07:55
04/26/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Sajan »

Sajan trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

Labarge

$50.60

-0.09 (-0.18%)

07:54
04/26/17
04/26
07:54
04/26/17
07:54
Upgrade
Labarge rating change  »

L Brands upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOKF

BOK Financial

$80.29

0.69 (0.87%)

07:54
04/26/17
04/26
07:54
04/26/17
07:54
Earnings
BOK Financial reports Q1 EPS $1.35, consensus $1.05 »

Steven G. Bradshaw,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

VIAB

Viacom

$42.95

0.2 (0.47%)

07:53
04/26/17
04/26
07:53
04/26/17
07:53
Recommendations
Viacom analyst commentary  »

Viacom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

AAPL

Apple

$144.53

0.89 (0.62%)

, SSNLF

Samsung

07:52
04/26/17
04/26
07:52
04/26/17
07:52
Periodicals
Apple plans to replace OLED with micro-LED in Apple Watch 3, Apple Insider says »

Apple (AAPL) is…

AAPL

Apple

$144.53

0.89 (0.62%)

SSNLF

Samsung

LPL

LG Display

$13.88

0.5 (3.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

GLW

Corning

$28.54

1.02 (3.71%)

, VZ

Verizon

$46.70

-0.35 (-0.74%)

07:52
04/26/17
04/26
07:52
04/26/17
07:52
Recommendations
Corning, Verizon analyst commentary  »

Corning doing better than…

GLW

Corning

$28.54

1.02 (3.71%)

VZ

Verizon

$46.70

-0.35 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 31

    May

  • 16

    Jun

DD

DuPont

$82.21

2.84 (3.58%)

07:51
04/26/17
04/26
07:51
04/26/17
07:51
Recommendations
DuPont analyst commentary  »

DuPont price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 31

    May

SPGI

S&P Global

$135.61

1.71 (1.28%)

07:50
04/26/17
04/26
07:50
04/26/17
07:50
Recommendations
S&P Global analyst commentary  »

S&P Global price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

07:50
04/26/17
04/26
07:50
04/26/17
07:50
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BDX

Becton Dickinson

$179.07

2 (1.13%)

, RHHBY

Roche

$32.41

0.397 (1.24%)

07:49
04/26/17
04/26
07:49
04/26/17
07:49
Hot Stocks
Becton Dickinson licenses novel molecular indexing technology to Roche »

Becton Dickinson (BDX)…

BDX

Becton Dickinson

$179.07

2 (1.13%)

RHHBY

Roche

$32.41

0.397 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

HUM

Humana

$217.97

4.21 (1.97%)

07:49
04/26/17
04/26
07:49
04/26/17
07:49
Recommendations
Humana analyst commentary  »

Humana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 16

    May

  • 13

    Jun

07:47
04/26/17
04/26
07:47
04/26/17
07:47
General news
Futures little changed as earnings parade marches on »

Stock futures are off…

CAT

Caterpillar

$104.42

7.61 (7.86%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
Caterpillar analyst commentary  »

Caterpillar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

MCD

McDonald's

$141.70

7.47 (5.57%)

07:46
04/26/17
04/26
07:46
04/26/17
07:46
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SAP

SAP

$102.13

0.75 (0.74%)

07:45
04/26/17
04/26
07:45
04/26/17
07:45
Downgrade
SAP rating change  »

SAP downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:44
04/26/17
04/26
07:44
04/26/17
07:44
Earnings
Fiat Chrysler confirms FY17 guidance for revenue, EBIT »

The Group confirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$59.29

0.64 (1.09%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SYBT

S.Y. Bancorp

$42.30

0.85 (2.05%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
S.Y. Bancorp reports Q1 EPS 47c, consensus 45c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

CBOE

CBOE Holdings

$84.16

0.32 (0.38%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Syndicate
CBOE Holdings 2.25M share Block Trade; price range $83.25-$83.75 »

Jefferies is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

FCAU

Fiat Chrysler

$10.54

-0.02 (-0.19%)

07:43
04/26/17
04/26
07:43
04/26/17
07:43
Earnings
Fiat Chrysler reports Q1 adjusted EBIT EU1.54B, consensus EU1.44B »

Reports Q1 revenues of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$54.31

0.5 (0.93%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$19.45

-0.3083 (-1.56%)

07:42
04/26/17
04/26
07:42
04/26/17
07:42
Periodicals
Embraer partners with Uber to develop electric vehicles, Reuters reports »

Brazilian planemaker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$60.10

0.24 (0.40%)

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Silgan Holdings raises FY17 adj. EPS view to $3.20-$3.40 from $3.15-$3.35 »

Silgan Holdings increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

SAH

Sonic Automotive

07:41
04/26/17
04/26
07:41
04/26/17
07:41
Earnings
Sonic Automotive reports Q1 adjusted EPS 23c, consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 20

    Jun

MMM

3M

07:40
04/26/17
04/26
07:40
04/26/17
07:40
Recommendations
3M analyst commentary  »

3M price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.